Condition: TBI Traumatic Brain Injury · Sponsor: Mansoura University
Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.
This description comes directly from the study's public registry record.
Aya Osama Nagaty · 00201097721011 · doctoraya_15@yahoo.com
Always discuss trial participation with your own doctor first.
| Zagazig University Hospitals, Zagazig, | Zagazig, Egypt | Recruiting |
| Zagazig University Hospitals | Zagazig, Egypt | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06836856